Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
On track to initiate dosing by early November 2026; topline Phase 1 proof-of-mechanism data anticipated approximately six months following study initiation
Covered in this story
Call it yourself
No calls on $EQ yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Equillium →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.